Pfizer Inc (PFE)

PFE on New York Consolidated

29.77USD
29 Sep 2014
Price Change (% chg)

$0.05 (+0.17%)
Prev Close
$29.72
Open
$29.67
Day's High
$29.84
Day's Low
$29.57
Volume
19,969,777
Avg. Vol
22,874,535
52-wk High
$32.96
52-wk Low
$27.87

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.68
Market Cap (Mil.): $188,767.50
Shares Outstanding (Mil.): 6,340.86
Dividend: 0.26
Yield (%): 3.49

Financials

  PFE Industry Sector
P/E (TTM): 18.78 33.13 33.86
EPS (TTM): 1.59 -- --
ROI: 6.80 18.19 17.43
ROE: 13.38 18.89 18.28
Search Stocks

Pfizer drug effective in patients with rare lung cancer: study

- Pfizer Inc's Xalkori, which treats lung cancer patients with a specific gene mutation, proved effective in shrinking tumors in those with an even rarer form of the disease, according to data presented at a medical meeting on Saturday.

27 Sep 2014

Pfizer drug effective in patients with rare lung cancer -study

Sept 27 - Pfizer Inc's Xalkori, which treats lung cancer patients with a specific gene mutation, proved effective in shrinking tumors in those with an even rarer form of the disease, according to data presented at a medical meeting on Saturday.

27 Sep 2014

Fitch Affirms Pfizer's IDR at 'A+'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, September 26 (Fitch) Fitch Ratings has affirmed Pfizer Inc.'s (Pfizer's) ratings, including the 'A+' Issuer Default Rating (IDR). The rating actions apply to approximately $37.8 billion of consolidated debt outstanding as of June 29, 2014. The Rating Outlook is Stable. A full list of ratings follows at the end of this press release. KEY RATING DRIVERS --Fitch forecasts that Pfizer will operate with total debt leverage rangi

26 Sep 2014

New U.S. tax rules chill 'inversion' deal-making; shares dive

WASHINGTON/NEW YORK - Tough new U.S. government rules on corporate "inversion" deals, aimed at making the tax-avoidance transactions less desirable, undermined share prices in nearly a dozen companies on both sides of the Atlantic on Tuesday. | Video

23 Sep 2014

WRAPUP 3-New U.S. tax rules chill 'inversion' deal-making; shares dive

* Action may deter Pfizer from returning to bid for AstraZeneca (Adds Kies, Scalia comments, background, closing share prices)

23 Sep 2014

Deals of the day- Mergers and acquisitions

(Adds Deere, Pfizer, Pershing Square Capital Management, Spirit Pub, Alstom, Procter & Gamble, Total, ZF Friedrichshafen, WSE, Jost Group, Grupo Oi, Eurobank Ergasias, UniCredit and Telefonica)

23 Sep 2014

Pfizer approaches Actavis to gauge interest in deal: Bloomberg

- Pfizer Inc has approached Dublin-based generic drugmaker Actavis Plc to express its interest in an acquisition, Bloomberg reported, citing people with knowledge of the matter.

23 Sep 2014

WRAPUP 2-New U.S. tax rules chill 'inversion' deal-making; shares dive

* Action may deter Pfizer from returning to bid for AstraZeneca (Recasts with Medtronic comments, update stock moves)

23 Sep 2014

WRAPUP 1-Shares of 'inversion' candidates slide on U.S. tax rule

* Action may deter Pfizer from returning to bid for AstraZeneca

23 Sep 2014

REPEAT-UPDATE 2-AstraZeneca, Shire dive as U.S. tax move punctures deal hopes

* Seen as possible threat to Shire's agreed sale to AbbVie

23 Sep 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $106.54 -0.56
Novartis AG (NOVN.VX) CHF89.80 +0.70
Merck & Co., Inc. (MRK.N) $59.41 +0.02
Roche Holding Ltd. (ROG.VX) CHF280.60 -0.10
Abbott Laboratories (ABT.N) $41.90 -0.11
Bayer AG (BAYGn.DE) €95.41 -2.28
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €88.99 +1.38
AstraZeneca plc (AZN.L) 4,428.50p -17.50
GlaxoSmithKline plc (GSK.L) 1,418.00p -2.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks